Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common shares in the United States.

The number of common shares to be sold and the price range for the proposed offering have not yet been determined. The Company has filed an application to list its common shares on the Nasdaq Capital Market under the symbol "OPTH." The filing of the application does not guarantee the listing of the Company's common shares, and the Company may withdraw its application due to future circumstances, market conditions or other factors.

Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the proposed offering.

The offering will be made only by means of a prospectus forming a part of the registration statement. Copies of the preliminary prospectus relating to the proposed offering may be obtained, when available, from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 1000, by phone at (929) 833-1246 or by email to prospectus@titanpartnersgrp.com.

A registration statement on Form F-1 (File Number: 333-290086) relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This communication to the market shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. The proposed offering is subject to market and other conditions and the completion of the SEC's review process. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.